STOCK TITAN

OKYO Pharma (OKYO) director reports detailed stock option grants

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

OKYO Pharma Ltd director Bernard Denoyer filed an initial ownership report showing multiple option grants over OKYO common stock. The options have exercise prices ranging from $1.46 to $2.13 per share and expire between 2033 and 2035. Examples include options over 3,750 underlying shares at $1.50 expiring in 2035 and options over 3,334 underlying shares at $1.46 expiring in 2034.

Positive

  • None.

Negative

  • None.
Insider Denoyer Bernard
Role null
Type Security Shares Price Value
holding Options -- -- --
holding Options -- -- --
holding Options -- -- --
holding Options -- -- --
holding Options -- -- --
holding Options -- -- --
holding Options -- -- --
holding Options -- -- --
holding Options -- -- --
holding Options -- -- --
holding Options -- -- --
holding Options -- -- --
holding Options -- -- --
holding Options -- -- --
Holdings After Transaction: Options — 770 shares (Direct, null)
Footnotes (1)
Option exercise price $1.50/share Options over 3,750 underlying common shares expiring 2035-03-25
Underlying shares 3,334 shares Options at $1.46 exercise price expiring 2034-03-13
Option exercise price $1.60/share Options over 1,205 underlying shares expiring 2035-01-29
Option exercise price $2.13/share Options over 770 underlying shares expiring 2033-03-14
Transaction classification 14 holding entries Form 3 transactionSummary, all coded as holdings
Options financial
"security_title": "Options""
Options are contracts that give investors the right to buy or sell an asset at a specific price within a certain time frame. They function like a reservation or a ticket that allows for potential profit or protection against price changes, making them useful tools for managing investment risks or speculating on market movements.
exercise price financial
"conversion_or_exercise_price": "1.5000""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
underlying security financial
"underlying_security_title": "common stock""
expiration date financial
"expiration_date": "2035-03-25T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
transaction_type financial
"transaction_type": "holding""
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Denoyer Bernard

(Last)(First)(Middle)
C/O OKYO PHARMA LTD,
14-15 CONDUIT STREET

(Street)
LONDONW1S 2XJ

(City)(State)(Zip)

UNITED KINGDOM

(Country)
2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026
3. Issuer Name and Ticker or Trading Symbol
OKYO Pharma Ltd [ OKYO ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Options03/14/202403/14/2033common stock770$2.13D
Options03/14/202503/14/2033common stock769$2.13D
Options03/14/202603/14/2033common stock769$2.13D
Options03/14/202703/14/2033common stock769$2.13D
Options03/13/202503/13/2034common stock3,333$1.46D
Options03/13/202603/13/2034common stock3,334$1.46D
Options03/13/202703/13/2034common stock3,333$1.46D
Options01/29/202601/29/2035common stock1,204$1.6D
Options01/29/202701/29/2035common stock1,204$1.6D
Options01/29/202801/29/2035common stock1,205$1.6D
Options03/25/202603/25/2035common stock3,750$1.5D
Options03/25/202703/25/2035common stock3,750$1.5D
Options03/25/202803/25/2035common stock3,750$1.5D
Options03/25/202903/25/2035common stock3,750$1.5D
Explanation of Responses:
/s/ Bernard Denoyer06/02/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Bernard Denoyer’s Form 3 filing for OKYO Pharma report?

The Form 3 filing reports Bernard Denoyer’s existing holdings of stock options over OKYO Pharma common shares. It lists multiple option grants with specific exercise prices, underlying share amounts, and expiration dates, establishing his baseline derivative position as a company director.

What option exercise prices are disclosed for OKYO Pharma (OKYO) director Bernard Denoyer?

The filing shows stock options with exercise prices of $1.46, $1.50, $1.60, and $2.13 per share. Each grant is tied to a distinct set of underlying common shares and a separate expiration date between 2033 and 2035.

When do Bernard Denoyer’s reported OKYO Pharma stock options expire?

The options reported in the Form 3 expire between 2033-03-14 and 2035-03-25. Each option series lists a specific expiration date, with later-dated grants generally having exercise prices of $1.50 or $1.60 per share over OKYO common stock.

How many underlying OKYO Pharma common shares are tied to Bernard Denoyer’s options?

Each option entry specifies underlying common shares, such as 3,750 shares at a $1.50 exercise price, 3,334 shares at $1.46, and 770 shares at $2.13. The Form 3 lists multiple such grants rather than one combined total.

Does the OKYO Pharma Form 3 show any recent insider buying or selling by Bernard Denoyer?

The Form 3 functions as an initial ownership report and shows holdings classified as “holding” transactions. It does not identify any entries as open-market purchases or sales; it simply lists existing option positions with exercise prices, share counts, and expiration dates.